Neovascular (Wet) Age-Related Macular Degeneration Clinical Trial
Official title:
A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
The primary objectives of the study are to determine the safety of high-dose aflibercept (hereafter referred to as HD) and to determine if HD provides greater intraocular pharmacodynamic (PD) effect and/or longer duration of action compared to intravitreal aflibercept injection (hereafter referred to as IAI).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06184360 -
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
||
| Completed |
NCT04847895 -
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
|
||
| Active, not recruiting |
NCT05439629 -
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
|
Phase 3 | |
| Recruiting |
NCT05197270 -
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Terminated |
NCT05473715 -
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
|
Phase 4 | |
| Recruiting |
NCT06346600 -
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
|